Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates
Can-Fite provided an update on the regulatory status of its lead candidates, Namodenoson and Piclidenoson, confirming their advancement in Phase III programs under FDA and EMA frameworks. Namodenoson holds FDA Fast Track and U.S. and European Orphan Drug designations for its pivotal Phase III study in advanced liver cancer (HCC) with underlying liver cirrhosis.
Key figures
- Drug Name
- Namodenoson, Piclidenoson
- Phase Of Trial
- Phase III
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.